Phospho-PAK2 (Ser197) Antibody

What is Phospho-PAK2 (Ser197) Antibody and what does it specifically detect?

Phospho-PAK2 (Ser197) antibody specifically recognizes PAK2 protein only when phosphorylated at serine 197. This antibody is designed to detect endogenous levels of PAK2 in its phosphorylated state at this specific residue. The antibody is typically generated using synthetic phosphopeptides derived from human PAK2 around the phosphorylation site of Serine 197 (typically encompassing amino acids 163-212, with the sequence approximating T-R-S(p)-V-I) . This high specificity makes it an invaluable tool for studying PAK2 activation states in various signaling cascades. The antibody does not cross-react with non-phosphorylated PAK2 or other proteins, providing clean and specific detection of this phosphorylation event in biological samples .

What species reactivity does the Phospho-PAK2 (Ser197) antibody exhibit?

Most commercial Phospho-PAK2 (Ser197) antibodies demonstrate reactivity across multiple mammalian species, specifically:

• Human

• Mouse

• Rat

What are the validated applications for Phospho-PAK2 (Ser197) antibody?

The Phospho-PAK2 (Ser197) antibody has been validated for several research applications:

Each application requires specific optimization for your particular experimental system. The antibody has been particularly well-validated for immunohistochemical analysis of paraffin-embedded tissues, including human breast carcinoma samples . When performing immunohistochemistry, appropriate blocking controls using the phospho-peptide immunogen should be included to confirm specificity of staining patterns .

How should Phospho-PAK2 (Ser197) antibody be stored and handled to maintain optimal activity?

For optimal performance and longevity of the Phospho-PAK2 (Ser197) antibody, follow these storage and handling protocols:

• Long-term storage: Store at -20°C for up to one year from the date of receipt .

• Working stock: For frequent use over short periods (up to one month), store at 4°C to avoid repeated freeze-thaw cycles .

• Avoid repeated freeze-thaw cycles as they can lead to antibody degradation and loss of activity .

• The antibody is typically supplied in a buffer containing PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain stability .

• When working with the antibody, keep it on ice and return to appropriate storage conditions promptly after use.

• Ensure proper aliquoting upon first thaw if multiple experiments are planned over time to minimize freeze-thaw cycles .

What are the recommended protocols for using Phospho-PAK2 (Ser197) antibody in immunohistochemistry?

For optimal results when using Phospho-PAK2 (Ser197) antibody in immunohistochemistry applications:

• Tissue Preparation:

  • Fix tissues in 10% neutral buffered formalin

  • Process and embed in paraffin

  • Section at 4-6μm thickness

• Antigen Retrieval:

  • Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 8.0)

  • Heat in a pressure cooker or microwave until boiling, then maintain at sub-boiling temperature for 10-20 minutes

  • Cool sections to room temperature

• Blocking and Antibody Incubation:

  • Block endogenous peroxidase with 3% H₂O₂ in methanol for 15 minutes

  • Block non-specific binding with 5% normal serum in PBS for 1 hour

  • Apply primary antibody at 1:100-1:300 dilution in blocking buffer

  • Incubate overnight at 4°C or 1-2 hours at room temperature in a humidified chamber

• Detection:

  • Use appropriate HRP-conjugated secondary antibody system

  • Visualize with DAB substrate

  • Counterstain with hematoxylin

  • Mount with permanent mounting medium

• Controls:

  • Include a phospho-peptide blocking control by pre-incubating the antibody with the phosphopeptide immunogen

  • Include positive control tissues (human breast carcinoma has been validated)

  • Include a negative control by omitting primary antibody

This protocol has been validated for detecting phosphorylated PAK2 at Ser197 in human, mouse, and rat tissue samples, with specific validation shown in human breast carcinoma tissues .

How can I optimize the signal-to-noise ratio when using Phospho-PAK2 (Ser197) antibody?

Optimizing signal-to-noise ratio is crucial when working with phospho-specific antibodies like Phospho-PAK2 (Ser197):

• Sample Preparation:

  • Ensure rapid fixation of samples to preserve phosphorylation states

  • Include phosphatase inhibitors in all buffers during protein extraction

  • Process samples quickly to minimize dephosphorylation

• Antibody Dilution Optimization:

  • Perform a dilution series (e.g., 1:50, 1:100, 1:200, 1:300, 1:500) to determine optimal concentration

  • The recommended starting dilutions are:

    • IHC: 1:100-1:300

    • ELISA: 1:5000

    • IF: 1:50-1:200

• Blocking Optimization:

  • Use 3-5% BSA instead of milk for blocking and antibody dilution (milk contains phosphoproteins)

  • Consider adding 0.1% Tween-20 to reduce non-specific binding

• Incubation Conditions:

  • Longer incubation at 4°C (overnight) often gives better signal-to-noise ratio than shorter incubations at room temperature

  • Ensure even coverage of antibody solution over the tissue/cells

• Validation Controls:

  • Include a phospho-peptide blocking control to confirm specific binding

  • Use tissues known to express phosphorylated PAK2 as positive controls

  • Consider using PAK2 knockdown or knockout samples as negative controls

• Washing Steps:

  • Increase number and duration of washes (3-5 washes of 5-10 minutes each)

  • Use TBS-T (Tris-buffered saline with 0.1% Tween-20) for more stringent washing

By methodically optimizing these parameters, researchers can achieve specific detection of phosphorylated PAK2 at Ser197 with minimal background interference in their experimental systems .

What is the biological significance of PAK2 phosphorylation at Ser197?

Phosphorylation of PAK2 at Serine 197 represents a critical regulatory mechanism in PAK2 signaling pathways. PAK2 (p21-activated kinase 2) is a 58 kDa serine/threonine kinase belonging to the PAK family that functions as an effector of Cdc42 and Rac1 small GTPases . The biological significance of Ser197 phosphorylation includes:

• Activation Mechanism: Ser197 phosphorylation is part of the activation process of PAK2, which occurs through autophosphorylation following binding of GTP-bound Cdc42 or Rac1 to the p21-binding domain (PBD) of PAK2. This interaction relieves auto-inhibition, allowing PAK2 to adopt an active conformation .

• Regulation of Kinase Activity: Phosphorylation at Ser197 contributes to the regulation of PAK2's kinase activity toward downstream substrates involved in cytoskeletal reorganization, cell motility, and cell survival pathways .

• Relationship to Apoptotic Cleavage: During apoptosis, PAK2 is proteolytically cleaved by caspase-3 to yield PAK-2p27 and PAK-2p34 fragments. The phosphorylation status at Ser197 may influence this cleavage or the subsequent activity of these fragments .

• Cellular Localization: Phosphorylation at Ser197 may affect the subcellular localization of PAK2, influencing its access to substrates and interaction partners within different cellular compartments.

Understanding the phosphorylation state of PAK2 at Ser197 provides valuable insights into cellular signaling networks involved in cancer progression, cytoskeletal dynamics, and apoptotic responses .

How does PAK2 phosphorylation at Ser197 differ from other PAK2 phosphorylation sites?

PAK2 undergoes phosphorylation at multiple sites, each with distinct functional consequences. The phosphorylation at Ser197 has several distinguishing characteristics:

• Location in Protein Structure:

  • Ser197 is located within the regulatory region of PAK2 (amino acids 163-212)

  • This differs from other key phosphorylation sites such as Thr402, which is within the activation loop of the kinase domain

• Functional Role:

  • Ser197 phosphorylation is associated with early stages of PAK2 activation

  • In contrast, phosphorylation at Thr402 in the activation loop is essential for full catalytic activity

  • Other sites like Ser20 are involved in different regulatory mechanisms including interaction with adaptor proteins

• Regulation Mechanism:

  • Ser197 phosphorylation occurs through autophosphorylation in response to GTPase binding

  • This differs from sites that are targeted by upstream kinases in signaling cascades

• Temporal Dynamics:

  • Ser197 phosphorylation may precede phosphorylation at other sites during the activation sequence

  • The order of phosphorylation events contributes to the precise regulation of PAK2 activity

• Protein Conformation Effects:

  • Phosphorylation at Ser197 induces specific conformational changes that differ from those induced by phosphorylation at other sites

  • These conformational differences affect PAK2's interaction with substrates and regulatory proteins

Understanding these distinctions is crucial for interpreting experimental results and designing studies to investigate specific aspects of PAK2 regulation in cellular signaling pathways .

What are the major upstream regulators and downstream effectors of PAK2 phosphorylation at Ser197?

The phosphorylation of PAK2 at Ser197 occurs within a complex signaling network involving multiple upstream regulators and downstream effectors:

Upstream Regulators:

• Small GTPases:

  • Cdc42 and Rac1 are the primary activators that promote PAK2 autophosphorylation at Ser197

  • Upon GTP loading, these GTPases bind to the p21-binding domain (PBD) of PAK2, relieving auto-inhibition

• Growth Factor Signaling:

  • Receptor tyrosine kinases (RTKs) activated by growth factors like EGF, PDGF

  • These activate Rac1/Cdc42 through guanine nucleotide exchange factors (GEFs)

• Lipid Messengers:

  • Phosphoinositides, particularly PIP3, can facilitate membrane recruitment and activation

  • Sphingolipid metabolites may modulate PAK2 activity in certain contexts

Downstream Effectors:

• Cytoskeletal Regulators:

  • LIM kinase (LIMK), which inactivates cofilin to regulate actin dynamics

  • Filamin A, which influences actin crosslinking and cell migration

  • Myosin light chain (MLC), affecting contractility

• Cell Survival and Apoptosis:

  • BAD (Bcl-2-associated death promoter) phosphorylation, which inhibits its pro-apoptotic function

  • Caspase pathways, particularly during the formation of PAK-2p34 after caspase-mediated cleavage

• Transcriptional Regulation:

  • MEK/ERK pathway components

  • Nuclear factor-κB (NF-κB)

  • MAPK signaling cascade elements

• Cell Cycle Regulators:

  • Aurora kinase

  • Polo-like kinase 1 (PLK1)

  • Cyclin-dependent kinase (CDK) pathways

This intricate network positions PAK2 as a central node in signaling pathways that control cellular morphology, motility, survival, and proliferation. The phosphorylation status at Ser197 can therefore have wide-ranging effects on multiple cellular processes and pathways .

What are common issues when using Phospho-PAK2 (Ser197) antibody and how can they be resolved?

Researchers frequently encounter several challenges when working with Phospho-PAK2 (Ser197) antibody. Here are common issues and their solutions:

• Low or No Signal:

  • Cause: Dephosphorylation during sample preparation; insufficient antigen retrieval; degradation of antibody

  • Solution: Include phosphatase inhibitors in all buffers; optimize antigen retrieval conditions (try both citrate pH 6.0 and EDTA pH 8.0 buffers); confirm antibody viability with positive controls; increase antibody concentration or incubation time

• High Background:

  • Cause: Non-specific binding; excessive antibody concentration; inadequate blocking

  • Solution: Increase blocking time (2 hours at room temperature); use 3-5% BSA for blocking instead of serum; optimize antibody dilution (start with 1:200 for IHC); increase washing steps (5 washes of 5 minutes each); pre-absorb antibody with non-phosphorylated peptide

• Cross-reactivity with other Phospho-Proteins:

  • Cause: Similarity of phospho-epitopes across protein families; non-specific binding

  • Solution: Perform peptide competition assay with both phospho and non-phospho peptides; include knockout/knockdown controls; confirm specificity with alternative detection methods

• Inconsistent Results Between Experiments:

  • Cause: Variation in phosphorylation states; inconsistent sample handling

  • Solution: Standardize sample collection and fixation protocols; minimize time between tissue collection and fixation; use freshly prepared buffers with phosphatase inhibitors

• Poor Reproducibility in Different Cell/Tissue Types:

  • Cause: Variable expression levels; tissue-specific phosphatases

  • Solution: Validate antibody in each cell/tissue type; adjust antibody concentration based on expression level; include positive control tissues (e.g., human breast carcinoma)

By systematically addressing these issues through methodical troubleshooting, researchers can achieve reliable and consistent results with Phospho-PAK2 (Ser197) antibody across various experimental systems.

How can Phospho-PAK2 (Ser197) antibody be used in multiplexed immunofluorescence studies?

Multiplexed immunofluorescence with Phospho-PAK2 (Ser197) antibody enables simultaneous visualization of phosphorylated PAK2 in relation to other proteins and cellular structures. This approach provides valuable spatial and contextual information about PAK2 signaling networks:

• Antibody Compatibility Assessment:

  • Evaluate primary antibody host species to avoid cross-reactivity (Phospho-PAK2 (Ser197) antibody is typically rabbit-derived)

  • Select additional primary antibodies from different host species (mouse, goat, etc.)

  • If multiple rabbit antibodies must be used, consider sequential staining with direct labeling or tyramide signal amplification (TSA)

• Fluorophore Selection and Spectral Separation:

  • Choose fluorophores with minimal spectral overlap (e.g., FITC/Alexa488, TRITC/Cy3, Cy5/Alexa647)

  • For Phospho-PAK2 (Ser197), consider using bright fluorophores like Alexa555 or Alexa594 for optimal detection of phospho-epitopes

  • Include appropriate single-color controls to assess and correct for spectral bleed-through

• Optimized Protocol:

  • Perform antigen retrieval suitable for all target antigens

  • Block with 5% normal serum from species corresponding to secondary antibodies

  • Apply Phospho-PAK2 (Ser197) antibody at 1:50-1:200 dilution

  • Co-incubate with other primary antibodies or apply sequentially if cross-reactivity is a concern

  • Include DAPI nuclear counterstain for cellular context

• Co-localization Analysis:

  • Examine co-localization between phosphorylated PAK2 and:

    • Cytoskeletal components (actin, tubulin) to assess relationship with cell architecture

    • Upstream regulators (Cdc42, Rac1) to confirm pathway activation

    • Downstream targets to validate signaling outcomes

  • Quantify co-localization using Pearson's or Mander's coefficients

• Technical Considerations:

  • Implement careful washing between antibody applications to minimize cross-reactivity

  • Consider using tyramide signal amplification for detection of low-abundance phospho-epitopes

  • Image using confocal or super-resolution microscopy for precise spatial localization

This multiplexed approach provides valuable insights into the spatial organization and contextual regulation of PAK2 phosphorylation at Ser197 in relation to other cellular components and signaling molecules .

How can I quantitatively assess PAK2 phosphorylation at Ser197 in various experimental conditions?

Quantitative assessment of PAK2 phosphorylation at Ser197 is critical for understanding signaling dynamics in different experimental conditions. Several methodological approaches can be employed:

• ELISA-Based Quantification:

  • Develop a sandwich ELISA using capture antibody against total PAK2 and detection with Phospho-PAK2 (Ser197) antibody

  • Use at 1:5000 dilution for high sensitivity and specificity

  • Create standard curves using recombinant phosphorylated PAK2 protein

  • Normalize phospho-signal to total PAK2 levels measured in parallel samples

• Western Blot Densitometry:

  • Separate proteins by SDS-PAGE and transfer to membranes

  • Probe with Phospho-PAK2 (Ser197) antibody

  • Strip and reprobe with total PAK2 antibody or run parallel blots

  • Quantify band intensities using image analysis software

  • Calculate phospho-PAK2/total PAK2 ratio to normalize for expression differences

• Quantitative Immunofluorescence:

  • Perform immunofluorescence staining with Phospho-PAK2 (Ser197) antibody at 1:50-1:200 dilution

  • Acquire images under identical exposure conditions

  • Measure mean fluorescence intensity in regions of interest

  • Subtract background signals and normalize to total PAK2 staining in parallel samples

  • Use nuclear counterstain for cell identification and normalization

• Flow Cytometry:

  • Fix and permeabilize cells appropriately to preserve phospho-epitopes

  • Stain with Phospho-PAK2 (Ser197) antibody followed by fluorophore-conjugated secondary antibody

  • Measure fluorescence intensity per cell

  • Generate histogram distributions to assess population heterogeneity

  • Calculate median fluorescence intensity for quantitative comparisons

• Phospho-Proteomic Mass Spectrometry:

  • Enrich for phosphopeptides using titanium dioxide or IMAC

  • Identify and quantify Ser197-phosphorylated PAK2 peptides

  • Use stable isotope labeling (SILAC, TMT) for precise relative quantification

  • Normalize to total PAK2 peptides for accurate comparison

For each method, it's essential to include appropriate controls:

• Positive controls: cells treated with agents known to activate PAK2 (e.g., growth factors)

• Negative controls: phosphatase-treated samples or PAK2 inhibitor-treated cells

• Peptide competition controls to verify antibody specificity

These quantitative approaches enable precise measurement of PAK2 Ser197 phosphorylation levels in response to various stimuli, inhibitors, or genetic manipulations.

How can Phospho-PAK2 (Ser197) antibody be used to investigate cancer signaling pathways?

Phospho-PAK2 (Ser197) antibody serves as a powerful tool for investigating cancer signaling pathways, particularly those involving cytoskeletal regulation, cell migration, and survival signaling:

• Cancer Cell Line Profiling:

  • Screen diverse cancer cell lines to establish baseline PAK2 Ser197 phosphorylation levels

  • Correlate phosphorylation status with invasive/metastatic potential

  • Perform immunohistochemistry on cancer tissues (validated in human breast carcinoma)

  • Compare PAK2 phosphorylation between matched normal and tumor tissues

• Signaling Pathway Analysis:

  • Examine PAK2 Ser197 phosphorylation in response to growth factors relevant to cancer (EGF, HGF, PDGF)

  • Investigate cross-talk with other oncogenic pathways (Ras/MAPK, PI3K/Akt)

  • Monitor PAK2 activation following cell adhesion to different extracellular matrix components

  • Assess pathway dynamics using time-course experiments after stimulation

• Drug Response Studies:

  • Evaluate PAK2 Ser197 phosphorylation changes in response to:

    • Small molecule PAK inhibitors

    • Cytoskeletal-targeting agents (microtubule inhibitors, actin disruptors)

    • Upstream pathway inhibitors (RTK inhibitors, PI3K inhibitors)

  • Correlate PAK2 phosphorylation with drug sensitivity profiles

• Functional Studies:

  • Introduce PAK2 mutations (particularly S197A phospho-deficient mutant)

  • Compare phenotypic effects (migration, invasion, survival) with phosphorylation status

  • Perform rescue experiments in PAK2-depleted cells with wild-type vs. phospho-mutant PAK2

  • Correlate changes in downstream substrate phosphorylation with Ser197 phosphorylation status

• Prognostic/Predictive Biomarker Development:

  • Analyze tissue microarrays using immunohistochemistry with Phospho-PAK2 (Ser197) antibody (1:100-1:300 dilution)

  • Correlate phosphorylation levels with clinical outcomes

  • Evaluate potential as a predictive biomarker for response to targeted therapies

This antibody has been validated in human breast carcinoma tissue, making it particularly valuable for breast cancer research . The ability to specifically detect PAK2 phosphorylation at Ser197 provides researchers with a precise readout of pathway activation status in cancer cells and tissues, potentially leading to new insights into cancer biology and therapeutic strategies.

What techniques can be used to validate the specificity of Phospho-PAK2 (Ser197) antibody in research applications?

Validating antibody specificity is crucial for ensuring reliable experimental results, especially for phospho-specific antibodies. For Phospho-PAK2 (Ser197) antibody, several complementary validation strategies should be employed:

• Peptide Competition Assays:

  • Pre-incubate the antibody with excess phosphorylated peptide (containing the Ser197 phosphosite)

  • In parallel, pre-incubate with non-phosphorylated peptide counterpart

  • Compare signal reduction between the two conditions

  • Complete signal abolishment with phospho-peptide but not with non-phospho peptide confirms specificity

• Genetic Approaches:

  • Use CRISPR/Cas9 or siRNA to knockdown/knockout PAK2

  • Express wild-type PAK2 vs. S197A mutant (cannot be phosphorylated)

  • Compare antibody reactivity across these conditions

  • True phospho-specific antibody should show no signal with S197A mutant

• Phosphatase Treatment:

  • Split samples and treat one set with lambda phosphatase

  • Compare antibody reactivity before and after phosphatase treatment

  • Signal should be eliminated or significantly reduced after phosphatase treatment

• Stimulation Experiments:

  • Treat cells with known activators of PAK2 (Rac1/Cdc42 activators)

  • Compare signal before and after stimulation

  • Phospho-specific signal should increase with stimulation

• Orthogonal Detection Methods:

  • Confirm phosphorylation using mass spectrometry-based phosphoproteomics

  • Compare results from Phospho-PAK2 (Ser197) antibody with alternative antibodies from different vendors or clones

  • Validate findings across multiple detection techniques (IHC, Western blot, ELISA)

• Application-Specific Validation:

  • For IHC: Perform antibody validation using tissue microarrays containing positive control tissues (e.g., human breast carcinoma)

  • For IF: Include counterstaining to verify expected subcellular localization

  • For Western blot: Confirm molecular weight and single band specificity

• Cross-reactivity Assessment:

  • Test antibody against related PAK family members (PAK1, PAK3) with similar phosphorylation sites

  • Examine potential cross-reactivity with other proteins containing similar phospho-epitopes

These validation approaches should be performed systematically and documented thoroughly to establish confidence in the specificity of the Phospho-PAK2 (Ser197) antibody for your particular experimental system and application .

How can Phospho-PAK2 (Ser197) antibody be used to study the role of PAK2 in neuronal development and function?

Phospho-PAK2 (Ser197) antibody enables investigation of PAK2's critical roles in neuronal development, plasticity, and function through various specialized techniques:

• Developmental Expression Profiling:

  • Track PAK2 Ser197 phosphorylation across developmental stages in neuronal cultures and brain tissues

  • Perform immunohistochemistry on brain sections at different developmental timepoints (using 1:100-1:300 dilution)

  • Compare phosphorylation patterns between different brain regions and neuronal subtypes

  • Correlate with periods of active neurite outgrowth and synaptogenesis

• Growth Cone Dynamics Studies:

  • Use immunofluorescence (1:50-1:200 dilution) to localize phosphorylated PAK2 in growth cones

  • Combine with live-cell imaging to correlate PAK2 phosphorylation with growth cone behavior

  • Examine co-localization with actin and microtubule cytoskeletal elements

  • Assess changes in phosphorylation following guidance cue stimulation (netrin, semaphorin, ephrin)

• Dendritic Spine Morphology Analysis:

  • Visualize phosphorylated PAK2 distribution in dendritic spines using super-resolution microscopy

  • Correlate Ser197 phosphorylation with spine morphology and maturation

  • Manipulate PAK2 phosphorylation (using S197A mutants or pharmacological approaches)

  • Assess consequences for spine development, stability, and plasticity

• Synaptic Plasticity Investigations:

  • Examine activity-dependent changes in PAK2 Ser197 phosphorylation

  • Apply stimulation protocols that induce LTP or LTD

  • Track temporal dynamics of phosphorylation following stimulation

  • Correlate with structural changes at synapses and functional outcomes

• Neurological Disorder Models:

  • Analyze PAK2 phosphorylation in animal models of neurodevelopmental disorders

  • Compare phosphorylation patterns in post-mortem brain samples from patients with neurological conditions

  • Assess PAK2 phosphorylation in response to therapeutic interventions

  • Investigate potential as a biomarker for disease progression or treatment response

• Integrative Approaches:

  • Combine phospho-PAK2 detection with electrophysiological recordings

  • Correlate phosphorylation status with functional outcomes

  • Implement optogenetic approaches to manipulate PAK2 activity with temporal precision

  • Utilize in vivo imaging to monitor PAK2 phosphorylation dynamics in intact neural circuits

The Phospho-PAK2 (Ser197) antibody's reactivity across human, mouse, and rat samples makes it particularly valuable for translational neuroscience research spanning from rodent models to human tissues . These approaches provide insights into PAK2's role in cytoskeletal regulation underlying neuronal development, connectivity, and function in both normal physiology and pathological conditions.

What are the most recent advances in understanding PAK2 phosphorylation and its applications in research?

Recent advances in understanding PAK2 phosphorylation at Ser197 have expanded our knowledge of its regulatory mechanisms and diverse functions across multiple biological contexts. These developments have significant implications for both basic research and potential therapeutic applications:

• Structural Biology Insights:

  • Advanced structural studies have provided detailed molecular mechanisms of how Ser197 phosphorylation affects PAK2 conformation

  • Cryo-EM and X-ray crystallography have revealed specific structural changes induced by phosphorylation at this site

  • These structural insights are facilitating structure-based drug design targeting PAK2

• Single-Cell Analysis Approaches:

  • Implementation of single-cell phosphoproteomics has revealed heterogeneity in PAK2 phosphorylation within seemingly uniform cell populations

  • Advanced imaging techniques allow visualization of PAK2 phosphorylation dynamics in real-time at the single-cell level

  • These approaches demonstrate the importance of considering cellular heterogeneity in PAK2 signaling

• Expanded Role in Disease Contexts:

  • Newly identified connections between PAK2 Ser197 phosphorylation and various pathological conditions beyond cancer

  • Emerging roles in neurodegenerative diseases, metabolic disorders, and inflammatory conditions

  • Potential as a biomarker for disease progression and treatment response

• Technological Improvements in Detection:

  • Development of highly specific phospho-proteomic mass spectrometry approaches for absolute quantification of Ser197 phosphorylation

  • Creation of improved biosensors for live monitoring of PAK2 activation status

  • Enhanced multiplexed detection systems allowing simultaneous monitoring of multiple phosphorylation sites

• Therapeutic Targeting Strategies:

  • Design of small molecule inhibitors specifically targeting PAK2 in its Ser197-phosphorylated state

  • Development of degraders (PROTACs) targeting phosphorylated PAK2

  • Exploration of PAK2 as a druggable target in various disease contexts

These advances continue to expand our understanding of PAK2 regulation and function, while simultaneously opening new avenues for diagnostic and therapeutic applications in various disease contexts .

What resources and databases are available for researchers studying PAK2 phosphorylation?

Researchers investigating PAK2 phosphorylation at Ser197 have access to numerous specialized resources and databases that provide valuable information for experimental design and data interpretation:

• Protein Phosphorylation Databases:

  • PhosphoSitePlus (phosphosite.org): Comprehensive resource for PAK2 phosphorylation sites, including Ser197, with information on conservation, regulation, and biological significance

  • PHOSIDA (phosida.org): Database of phosphorylation sites with structural context and evolutionary conservation

  • PhosphoPep: Repository of phosphopeptides identified in mass spectrometry studies

• Protein Structure Resources:

  • Protein Data Bank (PDB): Contains structural information on PAK2 and related kinases

  • AlphaFold DB: Provides predicted structures of PAK2 including regions around Ser197

  • MobiDB: Information on intrinsically disordered regions in PAK2 that may influence phosphorylation dynamics

• Pathway and Interaction Databases:

  • Reactome: Detailed pathway information for PAK2 signaling networks

  • STRING: Protein-protein interaction network data for PAK2

  • BioGRID: Curated interaction data for PAK2 and its partners

• Expression and Tissue Distribution:

  • Human Protein Atlas: Tissue expression patterns of PAK2 and antibody validation data

  • GTEX Portal: Tissue-specific expression data for PAK2 across human tissues

  • Allen Brain Atlas: Neuroanatomical expression patterns in brain tissue

• Disease Associations:

  • COSMIC: Somatic mutations in PAK2 in cancer

  • cBioPortal: Cancer genomics data related to PAK2 alterations

  • OMIM: Genetic disorders associated with PAK2 dysfunction

• Antibody Validation Resources:

  • Antibodypedia: Information on available PAK2 antibodies and validation status

  • CiteAb: Citation data for antibodies targeting PAK2 and phospho-PAK2 (Ser197)

  • Antibody Registry: Standardized antibody identifiers for reproducible research

• Software Tools:

  • Scansite: Prediction of kinase-specific phosphorylation sites

  • NetPhos: Neural network-based phosphorylation site prediction

  • KinasePhos: Prediction of kinase-specific phosphorylation sites

These resources collectively provide researchers with a wealth of information to inform experimental design, data interpretation, and contextual understanding of PAK2 phosphorylation at Ser197 in various biological systems .

What are the best practices for reporting and documenting experiments using Phospho-PAK2 (Ser197) antibody in scientific publications?

Proper documentation and reporting of experiments using Phospho-PAK2 (Ser197) antibody are essential for reproducibility and scientific rigor. The following best practices should be implemented when publishing research utilizing this antibody:

• Comprehensive Antibody Information:

  • Report complete vendor information (manufacturer, catalog number, lot number)

  • Specify antibody type (polyclonal), host species (rabbit), and clonality

  • Describe the immunogen used to generate the antibody (synthetic phosphopeptide derived from human PAK2 around Ser197)

  • Include information on purification method (affinity purification against phospho-peptide)

• Validation Methods and Controls:

  • Detail validation experiments performed specific to your experimental system

  • Document phosphopeptide competition controls and their outcomes

  • Describe genetic controls (knockdown/knockout, phospho-mutants) utilized

  • Include phosphatase treatment controls where applicable

  • Provide representative images of positive and negative controls

• Experimental Protocols:

  • Provide complete and detailed protocols including:

    • Sample preparation methods

    • Antigen retrieval parameters for IHC/IF (buffer composition, pH, time, temperature)

    • Blocking conditions (reagent, concentration, duration)

    • Antibody dilution (1:100-1:300 for IHC, 1:5000 for ELISA, 1:50-1:200 for IF)

    • Incubation conditions (time, temperature, buffer composition)

    • Detection system specifications

  • Include buffer compositions, particularly noting inclusion of phosphatase inhibitors

• Imaging and Analysis Parameters:

  • Report acquisition settings (exposure times, gain settings, microscope specifications)

  • Describe image processing methods (software, algorithms, thresholding approach)

  • Detail quantification methods with statistical analysis parameters

  • Provide information on blinding and randomization procedures

• Repository Deposition:

  • Submit unprocessed original images to appropriate repositories

  • Provide access to raw data supporting quantitative analyses

  • Consider sharing detailed protocols on platforms like protocols.io

• Acknowledgment of Limitations:

  • Discuss potential cross-reactivity concerns

  • Address limitations in interpretation of results

  • Note any inconsistencies observed between different detection methods

  • Acknowledge batch effects or lot-to-lot variations encountered

• RRID Inclusion:

  • Include Research Resource Identifiers (RRIDs) for the antibody

  • This facilitates tracking of the specific reagent across the scientific literature